

pCODR Patient Advocacy Group Conflict of Interest Declarations

Name of registered patient advocacy group: Kidney Cancer Canada / Association canadienne du cancer du rein

Name of drug and indication under review: Votrient / pazopanib for metastatic renal cell carcinoma

Conflict of Interest Declarations

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. Patient advocacy groups must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. Conflict of interest declaration is requested for transparency – it does not negate or preclude the use of the patient advocacy group input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry e.g., educational or research grants, honoraria, gifts, and salary;
- affiliations or personal or commercial relationships with drug manufacturers or other interest groups.

Section A: Payment Received

1. Has this patient advocacy group received any payments over the previous two years from any company or organization that may have direct or indirect interest in the drug under review?

- Yes
 No

If no, please go to Section B

2. What form of payment did this patient advocacy group receive? (Check all that apply.)

- | | | |
|---|---|---|
| <input checked="" type="checkbox"/> Operating Funds | <input checked="" type="checkbox"/> Program Funding (e.g., website) | <input type="checkbox"/> |
| <input type="checkbox"/> Royalties | <input type="checkbox"/> Research/educational grants | <input type="checkbox"/> |
| <input type="checkbox"/> Gifts | <input checked="" type="checkbox"/> Sponsorship of Events | <input type="checkbox"/> |
| <input type="checkbox"/> Honoraria | <input checked="" type="checkbox"/> Other, please specify: | Contribution to an endowment to support an annual memorial award in kidney cancer nursing to be presented each year at the Canadian Nurses in Oncology (CANO) conference. |

3. Please provide the names of companies and organizations and the amounts of the payments in the box below.

Note: Kidney Cancer Canada has chosen to declare all sources of support and income as well as all potential conflicts of interest that may influence or have the appearance of influencing the information submitted.

<i>Corporate Funding Sponsors (Healthcare Industry Only)¹</i>	<i>2010</i>	<i>2011 YTD</i>
AVEO Pharmaceuticals		
Bayer Healthcare		
GlaxoSmithKline		
Novartis Canada		
Pfizer Oncology		
Roche		
Rx&D		

<i>All Other Funding Resources</i>	<i>2010</i>	<i>2011 YTD</i>
Total charitable donations raised from individuals		
Corporate donors (non healthcare)		
Research funding match from CIHR SHOPP program		

<i>Non-Cash Resources</i>	<i>2010</i>	<i>2011 YTD</i>
Economic Valuation of Dedicated and Tracked Volunteer Hours 2010: 36,000 hours (75% management/25% admin) 2011: 20,000 hours YTD (75% management/25% admin) Valued according to Imagine Canada per: http://volunteercalculator.imaginecanada.ca/eng		

¹ KCC's Corporate Funding is governed by a strict code of conduct established by the International Kidney Cancer Coalition (IKCC) and posted on our website at this address: <http://www.kidneycancercanada.org/main.php?p=162>

Kidney Cancer Canada has adopted the Imagine Canada Code of Ethical Fundraising to uphold high standards of accountability and transparency. See: <http://www.imaginecanada.ca/en/node/21>

Section B: Holdings or Other Interests

Has this patient advocacy group received or is it in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list in the table below.

No member of the KCC Board of Directors is in possession of such stocks or options for organizations that may have a direct or indirect interest in the drug under review. As an organization, KCC owns no stocks or options.

Section C: Affiliations, personal or commercial relationships

Does this patient advocacy group have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below.

No member of the KCC Board of Directors has personal or commercial relationships of the nature stated above.

Similarly, no member of the KCC Board of Directors has personal or influential relationships with provincial cancer agencies, reimbursement agencies, or other government agencies that may have a direct financial interest in the drug under review.

I hereby certify that I have authority to disclose all relevant information with respect to any matter involving this patient advocacy group with a company, organization or entity that may place this patient advocacy group in a real, potential or perceived conflict of interest situation.

Date: July 27, 2011 Name: Deborah Maskens

Signature: 